EPRX vs CBIO
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
EPRX · Eupraxia Pharmaceuticals$6.89 ▲ 4.39%
CBIO · Crescent Biopharma$13.54 ▲ 4.64%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- EPRX +10.6%
- CBIO +3.3%
Head to head
| Metric | EPRX | CBIO |
|---|---|---|
| Price | $6.89 | $13.54 |
| Change today | ▲ 4.39% | ▲ 4.64% |
| Market cap | $455.25M | $502.93M |
| Return, 3 months | +3.5% | -21.9% |
| Return, year to date | -8.7% | +14.2% |
| Return, 1 year | +26.4% | +3.1% |
| P/E (TTM) | – | – |
| P/B | 4.5 | 3.2 |
| P/E percentile vs own 5y | 34th | 5th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -65.7% | -14.0% |
| Gross margin | – | – |
| Operating margin | – | -1,417.7% |
| Net margin | – | -1,389.6% |
| Return on equity | -111.0% | -112.1% |
| Analyst target vs. price | +146.7% | +134.5% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 46 | 49 |
| 30-day volatility | 85.1% | 65.1% |
| Max drawdown, 1 year | -35.9% | -56.1% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CBIO is the largest of the group by market value.
- EPRX has returned the most over the past year.
- CBIO has been the calmest stock over the last 30 days.